查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1304270

药物输送和遗传基因通知设备市场:各产品，成药，各地区:规模，占有率，展望，机会分析，2023年～2030年

Drug and Gene Delivery Devices Market, By Product, By Commercialized Drugs (Luxturna, Yescarta, Zolgensma, Kymriah, Provenge, and Strimvelis ), and By Geography - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030
出版日期: | 出版商: Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场动态:

传染病、心血管疾病、癌症和糖尿病等慢性病负担的不断增加，对药物输送和基因输送设备的需求不断增加，细胞和基因治疗的资金增加，以及基因治疗的批准增加，这些是预计的关键因素。在预测期内增强全球药物输送和基因输送设备市场的增长。

本调查的主要特征

  • 本报告提供以2021年为基准年的预测期间（2022-2030 年）之全球药物输送和遗传基因通知设备市场的市场规模和復合年增长率（CAGR %）相关的详细分析。
  • 并阐明不同部门市场的潜在收入机会，说明该市场具有魅力的投资主张矩阵。
  • 同时并提供市场推动因素和限制、机会、新产品发布或批准、市场趋势、区域前景和主要参与者采用的竞争战略等重要考察。
  • 并基于企业亮点，各类型投资组合、主要焦点、财务业绩和市场策略等参数，介绍全球药物输送和遗传基因通知设备市场的主要参与者之企业简介。
  • 藉由该报告提供的洞察，将能帮助营销人员和公司高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。
  • 全球药物输送和遗传基因通知设备市场报告配合该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以透过全球药物输送和遗传基因通知设备市场用于分析的各种战略矩阵来帮助他们更容易做下决策。

目录

第1章 调查目的与前提条件

  • 调查目的
  • 前提条件
  • 简称

第2章 市场概况

  • 报告概要
    • 市场定义和范围
  • 摘要整理
  • 连贯·机遇·地图(COM)

第3章 市场动态，法规，趋势分析

  • 市场动态
    • 全球慢性病负担增加
    • 严格的规章制度
    • 对药物和基因输送设备的需求不断增加
  • 影响分析
  • 主要的焦点
  • 法规情势
  • 产品上市/核准
  • PEST分析
  • 波特分析
  • 合併·收购情势

第4章 药物输送和遗传基因通知设备的全球市场-冠状病毒(COVID-19)流行的影响

  • COVID-19流行病学
  • 供给面和需求面的分析
  • 经济影响

第5章 药物输送和遗传基因通知设备的全球市场:各产品，2018-2030年

  • 视网膜下注射导管
  • 延长管
  • 静脉导管
  • 杀菌胰岛素注射器
  • 预填充式注射器
  • 输液袋子

第6章 药物输送和遗传基因通知设备的全球市场:成药，2018年～2030年

  • Luxturna(药物输送设备)
  • Yescarta（药物输送装置）
  • Zolgensma（药物输送装置）
  • Kymriah（药物输送装置）
  • Provenge（药物输送装置）
  • Strimvelis（药物输送装置）

第7章 药物输送和遗传基因通知设备的全球市场:各地区，2018年～2030年

  • 北美
  • 南美
  • 欧洲
  • 亚太地区
  • 中东
  • 非洲

第8章 竞争情形

  • Pfizer, Inc.
  • Novartis AG
  • Kite Pharma, Inc.
  • Bluebird bio, Inc.
  • Vericel Corporation
  • uniQure N.V.
  • Spark Therapeutics, Inc.
  • Renova Therapeutics
  • Orchard Therapeutics plc
  • Kolon Tissue Gene, Inc.
  • Human Stem Cell Institute
  • Amgen, Inc.
  • Dendreon Pharmaceuticals
  • Helixmith Co.
  • Bausch & Lomb Incorporated, Ltd.(ViroMed Co., Ltd.)
  • Becton Dickinson and Company
  • Castle Creek Biosciences, Inc.(Fibrocell Technologies, Inc.)

第9章 章节

  • 调查手法
  • 关于出版社
简介目录
Product Code: CMI5864

The field of drug and gene delivery involves the development and delivery of drugs, genes, and/or gene products that ultimately alter protein expression and function of the cells, tissues, and living organisms. Drug delivery devices are the tools used to deliver the drug through the specific route of administration. While, gene delivery is the process of introducing foreign genetic material, such as DNA or RNA, into host cells.

Market Dynamics:

Rise in burden of chronic diseases, such as infectious disease, cardiovascular disease, cancer, and diabetes, increasing demand for drug or gene delivery devices, increasing funding for cell and gene therapies, and rise in approvals for gene therapies are major factors expected to augment the growth of the global drug and gene delivery devices market over the forecast period.

For instance, in November 2022, Imunon, Inc. and Acuitas Therapeutics signed an agreement to evaluate the combination of IMUNON's PLACCINE nucleic acid vaccine constructs formulated with Acuitas' proprietary lipid delivery technology. Under the agreement, IMUNON will evaluate administration of its vector constructs formulated in various Acuitas LNP formulations for gene expression and immunogenicity in murine models.

Key features of the study:

  • This report provides in-depth analysis of the global drug and gene delivery devices market, and provides market size (US$ Thousand) and compound annual growth rate (CAGR%) for the forecast period (2023-2030), considering 2022 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global drug and gene delivery devices market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Pfizer, Inc., Novartis AG, Kite Pharma, Inc., Bluebird bio, Inc., Becton, Amgen, Inc., Vericel Corporation, uniQure N.V., Spark Therapeutics, Inc., Renova Therapeutics, Orchard Therapeutics plc, Kolon Tissue Gene, Inc., Human Stem Cell Institute, Dendreon Pharmaceuticals, Dickinson and Company, Helixmith Co., Ltd (ViroMed Co., Ltd), Bausch & Lomb Incorporated, and Castle Creek Biosciences, Inc (Fibrocell Technologies, Inc.), among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global drug and gene delivery devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug and gene delivery devices market.

Detailed Segmentation:

  • Global Drug and Gene Delivery Devices Market, By Product:
    • Sub-retinal Injection Cannula
    • Extension Tube
    • Intravenous Catheter
    • Sterile Insulin Syringe
    • Pre-filled Syringe
    • Infusion Bags
  • Global Drug and Gene Delivery Devices Market, By Commercialized Drugs:
    • Luxturna (Drug Delivery Devices)
    • Yescarta (Drug Delivery Devices)
    • Zolgensma (Drug Delivery Devices)
    • Kymriah (Drug Delivery Devices)
    • Provenge (Drug Delivery Devices)
    • Strimvelis (Drug Delivery Devices)
  • Global Drug and Gene Delivery Devices Market, By Region:
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East
    • Africa
  • Company Profiles:
    • Pfizer, Inc.
    • Novartis AG
    • Kite Pharma, Inc.
    • Bluebird bio, Inc.
    • Becton Dickinson and Company
    • Amgen, Inc.
    • Vericel Corporation
    • uniQure N.V.
    • Spark Therapeutics, Inc.
    • Renova Therapeutics
    • Orchard Therapeutics plc
    • Kolon Tissue Gene, Inc.
    • Human Stem Cell Institute
    • Dendreon Pharmaceuticals
    • Helixmith Co., Ltd (ViroMed Co., Ltd.)
    • Bausch & Lomb Incorporated
    • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product
    • Market Snapshot, By Commercialized Drugs
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Rise in burden of chronic diseases across the globe
    • Stringent rules and regulations
    • Increasing demand for drug and gene delivery devices
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Drug and Gene Delivery Devices Market - Impact of Coronavirus (COVID-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global Drug and Gene Delivery Devices Market, By Product, 2018-2030, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Sub-retinal Injection Cannula
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Extension Tube
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Intravenous Catheter
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Sterile Insulin Syringe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Pre-filled Syringe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Infusion Bags
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)

6. Global Drug and Gene Delivery Devices Market, By Commercialized Drugs, 2018-2030, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Luxturna (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Yescarta (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Zolgensma (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Kymriah (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Provenge (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)
  • Strimvelis (Drug Delivery Devices)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030,(US$ Thousand)

7. Global Drug and Gene Delivery Devices Market, By Region, 2018-2030, (US$ Thousand)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product, 2018-2030,(US$ Thousand)
    • Market Size and Forecast, and Y-o-Y Growth, By Commercialized Drugs, 2018-2030,(US$ Thousand)

8. Competitive Landscape

  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kite Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bluebird bio, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Vericel Corporation
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • uniQure N.V.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Spark Therapeutics, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Renova Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Orchard Therapeutics plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Kolon Tissue Gene, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Human Stem Cell Institute
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Amgen, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dendreon Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Helixmith Co.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Bausch & Lomb Incorporated, Ltd. (ViroMed Co., Ltd.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Becton Dickinson and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Castle Creek Biosciences, Inc. (Fibrocell Technologies, Inc.)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

9. Section

  • Research Methodology
  • About us